VivoSeq
Other

Mortality

88

Pipeline Programs↗

13

Active Trials↗

30

Companies Involved↗

Mortality is a moderately active landscape with 88 programs across 30 companies. The most active players are EMD Serono, Alnylam Pharmaceuticals, Neurim Pharmaceuticals Ltd.. 32 therapies are approved with 20 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

6/100

Mech. Concentration

9/100

Completion Rate

85/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2N

Neurim Pharmaceuticals Ltd.

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical31

Methylprednisolone

Pfizer

Dexamethasone

Aspen Global Incorporated

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Everolimus

Novartis

Zinc

American Regent, Inc.

Phase 1
No programs
Phase 25

Metformin

EMD Serono

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Hydroxychloroquine

Alnylam Pharmaceuticals

Melatonin

Neurim Pharmaceuticals Ltd.

Antiretroviral Combinations

Gilead

Phase 320

Tirzepatide

Eli Lilly

Sotatercept

Merck & Co.

Isoniazid

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Approved32

Desflurane

Baxter Healthcare Corporation

Propofol

Fresenius Kabi Oncology Ltd.

Valsartan

Novartis

Enoxaparin

Sanofi

Spironolactone

Pfizer

Analysis

Modality Breakdown

91%

Small molecule

91 of 100 classified programs — the dominant modality here.

9%ALL OTHERSVaccine55%Monoclonal antibody22%Protein / enzyme11%Peptide11%

Small molecule leads; the ring shows all 100 classified programs, each share of the total. Modality classified for 100% of 109 pipeline programs.

Analysis

Trial Status

97

clinical trials

Completed60 · 62%
Unknown status13 · 13%
Terminated9 · 9%
Recruiting7 · 7%
Active, not recruiting4 · 4%
Not yet recruiting2 · 2%
Other2 · 2%

Clinical Trials

Trial Activity

97 trials

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Recruiting·—·Phase 3·NCT05879276·164 enrolled
Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
Recruiting·PPopulation Health Research Institute·Phase 3·NCT05580666·8,000 enrolled
Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality
Recruiting·UUniversity Hospital, Montpellier·N/A·NCT07273643·30 enrolled
The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients
Recruiting·MMedical University of Graz·Phase 3·NCT03188796·2,400 enrolled
Factors Affecting Vaccine Prophylaxis Efficacy in Bone Marrow and Solid Organ Transplant Recipients: Impact on Infection and Mortality Rates
Recruiting·FFondazione IRCCS Policlinico San Matteo di Pavia·N/A·NCT07473999·200 enrolled
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Recruiting·PPr Bruno LEVY·Phase 3·NCT04020263·610 enrolled
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
Recruiting·—·Phase 3·NCT04588311·2,500 enrolled
Infant Mortality Reduction by the Mass Administration of Azithromycin
Active, not recruiting·UUniversity of California, San Francisco·Phase 4·NCT04716712·694,400 enrolled
Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?
Active, not recruiting·BBandim Health Project·Phase 4·NCT04658680·22,800 enrolled
Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali
Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT03909737·99,700 enrolled
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT05556512·15,374 enrolled
The Effects of Metformin on Morbidity and Mortality in Elderly Patients
Not yet recruiting·HHamilton Health Sciences Corporation·Phase 2·NCT04530058·250 enrolled
A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06572761·350 enrolled
The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age
Completed·BBandim Health Project·Phase 4·NCT01306006·3,500 enrolled
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
Completed·KKarolinska Institutet·N/A·NCT04412304·166 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)